Toxoplasma gondii is an obligate intracellular parasite capable of causing severe disease due to congenital infection and in patients with compromised immune systems. Control of infection is dependent on a robust Th1 type immune response including production of interferon gamma (IFN-γ), which is essential for control. IFN-γ activates a variety of anti-microbial mechanisms in host cells, which are then able to control intracellular parasites such as T. gondii. Despite the effectiveness of these pathways in controlling acute infection, the immune system is unable to eradicate chronic infections that can persist for life. Similarly, while antibiotic treatment can control acute infection, it is unable to eliminate chronic infection. To identify compounds that would act synergistically with IFN-γ, we performed a high-throughput screen of diverse small molecule libraries to identify inhibitors of T.
Introduction
Toxoplasma gondii is a widespread protozoal infection of animals that is transmitted by cats, which serve as the definitive host and shed oocysts into the environment (1) . Wild and domesticated herbivorous animals are readily infected by ingestion of oocysts, which are extremely resistant to environmental conditions (1) . Following a brief acute phase during which the parasite propagates as fast growing tachyzoites that disseminate to all organs of the body, the parasite differentiates into slow growing bradyzoites that reside in long-lived tissue cysts which form in differentiated cells such as neurons and muscle cells (2) . Infections can be passed vertically (3) , or through oral ingestion of tissue cysts due to omnivorous or carnivorous feeding (4) . Humans often become infected due to water or food born contamination (5, 6) or due to congenital infection (7) . Although most infection are benign, a large proportion of the world's human population is chronically infected (8) , putting them at risk of reactivation in the event of a decline in immune surveillance (9) Interferon gamma (IFN-γ) is the major cytokine responsible for driving the innate immune response to many intracellular pathogens (10) , including Toxoplasma gondii (11, 12) . There are multiple, overlapping pathways attributed to IFN-γ-dependent control of T. gondii growth in human cells, and the extent to which these operate in different cell types varies (13) . Pathways for IFN-γ-dependent control include induction of a non-canonical autophagy pathway that limits growth (14) , starvation by tryptophan degradation in the host cell (15) , upregulation of guanylate binding proteins that are recruited to the parasite containing vacuole (16) , ubiquitination and lysosomal clearance (17) , and induction of premature parasite egress (18) . Although the strong Th1 immune response associated with control of toxoplasmosis is beneficial, it also results in immunopathology due to inflammation, a syndrome commonly seen in ocular toxoplasmosis (19) . Current therapies for treatment of toxoplasmosis rely on inhibition of the folate pathway in the parasite, although macrolide antibiotics have also been used with some success (20) . Although these treatments are designed to block DNA replication and protein synthesis in the parasite, respectively, they are not effective in eliminating the tissue cyst forms that are responsible for chronic infection (21) . The effectiveness of these treatments is augmented by the immune response (22) , which contributes to control of acute infection but also cannot eradicate the chronic infection (23) .
To take advantage of the potential synergy between innate immunity and chemotherapy, we designed a screen to evaluate compounds for their ability to enhance the IFN-γ-dependent host response to T. gondii infection. Such combination treatments could potentially allow control at lower drug exposure and with fewer side effects associated with strong Th1 responses. The Broad Institute has previously synthesized close to 100,000 complex small molecules through diversity-oriented synthesis (DOS) for use in high throughput screening (HTS) (24, 25) . This DOS collection consists of a variety of different chemical skeletons and they are generally rich in sp3-hybridized carbon atoms (for increased 'natural product-likeness') compared to conventional small molecule libraries. We took advantage of this DOS collection and also screened inhibitors from commercial vendors to identify several chemical scaffolds that show enhanced IFN-γ-dependent control of T. gondii replication.
Results and Discussion

Development of a HTS for IFN-γ-dependent inhibitors of T. gondii growth
In order to identify compounds that would enhance the ability of IFN-γ to control Toxoplasma infection, two critical components were needed. First, we needed to identify the concentration of IFN-γ that would partially activate cells but not result in complete growth inhibition. Although recent studies indicate various concentrations restrict T.gondii growth in human cells (14, 18) , the concentration of IFN-γ required to partially restrict growth has not been identified. We determined the concentration of recombinant human IFN-γ required to limit replication of T. gondii in HeLa cells that were pre-activated for 24 h with different doses of human IFN-γ. The dose response curve exhibited a very sharp transition from low inhibition at low IFN-γ concentrations that very rapidly increased to maximum inhibition ( Fig. 1A ). Based on this response, we designed the primary screen and follow up validation assays to use doses of IFN-γ that resulted in an EC [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (Fig. 1A) . Second, to facilitate screening of larger compound collections, we miniaturized a growth assay based on a luciferase expressing parasite line to fit a 384-well format congruent with high throughput screen (HTS) platforms ( Fig. 1B) . We also added a 4h pre-incubation treatment to ensure compounds had the opportunity to promote cellular responses ( Fig. 1B ) prior to addition of T. gondii parasites. We then used this HTS to evaluate ~73,000 compounds to identify those that would enhance the innate immune response to T. gondii infection.
First, all ~73,000 compounds were screened in duplicate for growth inhibition (single point, 10 µM) in the presence of a low dose of IFN-γ (1.25 U/mL). To ensure the compounds were targeting the parasite and not the host cell, a cytotoxicity screen against HeLa cells was conducted in parallel ( Fig.   2 ). Removal of the cytotoxic compounds left 2,143 compounds that inhibited T. gondii growth by >50% at 10 µM, and < 50% host cell growth inhibition at a concentration of 20 µM. Next, these compounds were retested using an eight-point dose response growth inhibition assay to identify 880 active compounds that were then tested in the absence of IFN-γ ( Fig. 2 ). Comparison of these activities identified 80 compounds with an EC 50 values for parasite growth inhibition of < 10 µM, > 2 fold IFN-γ dependence, and toxicity to host cells > 20 µM ( Fig. 2 ). Structural clustering and structurally similar analogs were used to further refine the hit list to 72 compounds that showed IFN-γ-dependence ( Fig. 2, see Table S1 for complete data). A summary of the screening tree and compound prioritization is defined in Figure 2 .
Downstream assays to validate T. gondii inhibitors identified in the primary screen
In order to further evaluate the 72 compounds identified in the primary screen, compounds were resupplied to assure batch to batch consistency and tested in a single point assay (5 µM compound) in the presence vs. absence of low dose IFN-γ using the schematic shown in Figure 3A (Table S1 ). In total, 35 of 72 compounds were validated to inhibit growth of the tachyzoite stage of T. gondii in an IFNγ-dependent manner, although they differed in the fold change in the presence vs. absence of IFN-γ (Table S1 ). Vacuoles containing T. gondii parasites are normally devoid of LC3, but recruitment is dramatically enhanced by treatment with IFN-γ, resulting in growth impairment (14) . Hence, one potential mechanism for the IFN-γ-dependent inhibition would be increased recruitment of LC3. To determine the effect of the 72 compounds on LC3 recruitment, we developed an image-based screen to evaluate recruitment of GFP-LC3 to the parasite-containing vacuole (Fig. 3B ). Quantification of GFP-LC3 positive vacuoles revealed that in the presence of high levels of IFN-γ (50 U/mL), 12.4% of parasite-containing vacuoles were GFP-LC3 positive, compared with 0.63% of positive parasitecontaining vacuoles in a naïve HeLa cells ( Fig. 3C ). When evaluated using this image-based assay, a number of compounds enhanced LC3 recruitment to parasite containing vacuole ( Fig. 4 ). These inhibitors were grouped into three sets, depending on the extent to which they were IFN-γ dependent, enhanced LC3, or were simply growth inhibitors ( Fig 4A) , as described further below. Enhancement of LC3 recruitment was positively correlated with growth inhibition (Fig. 4B ). This pattern suggests that these compounds may act by enhancing the recruitment of a non-canonical autophagy pathway that was previously described to inhibit T. gondii growth in HeLa cells (14, 17) . However, among the most active inhibitors, there was not a strong correlation between LC3 recruitment and IFN-γ-dependent inhibition ( Fig. 4C ). Taken together, these findings indicate that the inhibitory properties of these compounds can be attributed both to enhanced LC3 recruitment and to IFN-γ dependence, yet these two pathways are largely independent.
The 35 compounds that were validated in these secondary screens were grouped into three sets based on their inhibition of growth, dependence on IFN-γ, and involvement of LC3 recruitment. Set one contains 15 compounds that show IFN-γ-dependent inhibition of 1.4 fold or greater ( Fig. 4A , Table S1 ), and approximately half these show enhanced LC3 recruitment ( Fig. 4A ). Set two contains 8 compounds that show enhanced LC3 recruitment but do not show marked IFN-γ-dependence ( Fig. 4A ).
Finally, set 3 contains 12 potent inhibitors that are neither IFN-γ-dependent nor enhance LC3 ( Fig. 4A ).
Because our primary interest was to identify compounds that were IFN-γ-dependent, we selected 15 compounds from sets 1 (n=11) and 2 (n=4) for further study (identified in black outlined symbols in Fig. Table S1 ) based on these properties as well as the chemical scaffolds they represent.
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SAR evaluation of lead compound series from IFN-γ dependent growth of inhibitors of T. gondii
To better understand the structural features important for IFN-γ-dependent growth inhibition of T. gondii, 61 analogs centered on the 15 prioritized hits were selected based on stereochemical properties and structural diversity (Table S2 ). We retested all 76 compounds (15 initial hits and 61 analogs) in a single point screen using 10 µM compound in the presence and absence of low dose IFN-γ (5 U/mL) in order to identify compound series that illustrated IFN-γ dependence across the series ( Fig. 5 , Table  S2 ). We visualized IFN-γ dependence for each molecule by plotting inhibition in the presence vs. absence of IFN-γ ( Fig. 5) . These values were compared to a regression line defined by a growthinhibiting dose of pyrimethamine (3 µM) and normal growth in a naïve HeLa cells (black line, Fig. 5 ).
Compounds that fall below the regression line showed a modest level of IFN-γ-dependence (red arrow) and the most potent molecules fall nearest the origin (black arrow). Interestingly, the majority of compounds from 6 chemical series fell outside the 95% confidence interval (CI, dashed black line) of the regression line as highlighted by the red quadrilateral in Fig. 5 . These 6 compound series that together comprise 32 analogs were selected for further evaluation in the presence and absence of low dose IFN-γ (Table S3 ). Testing EC 50 values confirmed that 5 of the 6 series displayed IFN-γ dependence including those series defined by the parent compounds BRD1354, BRD1871, BRD5675, BRD7522, and BRD0036 (Table S3 ). Of these compounds, three of them (i.e. BRD1354, BRD1871
and BRD5675) were also found to enhance GFP-LC3 recruitment (cutoff ≥ 2.7 fold, Table S1 ). These findings suggest that the activities of these compounds may involve other ATG proteins, although further studies would be required to confirm this dependence. Two chemical series, BRD1871 and BRD7522, were selected to further illustrate SAR patterns that govern IFN-γ dependence in enhancing T. gondii growth inhibition.
Compound series BRD1871 has three analogs that exhibit IFN-γ-dependent growth inhibition
The bridged bicyclic azetidine compound series exemplified by one of the original hits compound BRD1871 contained three stereochemical analogs that illustrated increased potency against T. gondii in the presence of low dose IFN-γ (blue bars) than in naïve HeLa cells (green bars) ( Fig. 6A ). Due to its potency, we could not determine IFN-γ dependence of BRD4137 in a single point assay, so we determined EC 50 values to determine the level of IFN-γ-dependence of each compound (Fig. 6B ). Both 
Analysis of stereoisomers of BRD7522 identifies stereo-selectivity of compound activity
Compound BRD7522 was one of the original hits that showed an EC 50 that was enhanced 2.1 fold by IFN-γ. BRD7522 contains a bicyclic moiety with a tri-substituted azetidine that has 3 stereocenters (at C1-3) and hence can give rise to a total of 8 possible stereoisomers ( Table 1 ). Most of the stereoisomers showed improved or comparable growth inhibitory activities against T. gondii in presence vs. absence of IFN-γ except for BRD6541 and BRD5882 (Table 1 ). These two compounds have the same configuration (R) on the stereocenter at C3 of the azetidine ring while having different configurations at C1 and C2. Changing the C1C2 configuration from RS/SR to SS (BRD7523) yielded similar potency both with and without IFN-γ stimulation (EC 50 4.46 µM and 4.14 µM respectively) ( Table   1 ). Switching the C1C2 configuration from RS/SR to RR (BRD0367 and BRD6698) led to slight increases in IFN-γ-dependent growth restriction of the parasite (Table 1) . However, the biggest increase in IFN-γ dependent fold changes were observed in the case of BRD4624 and BRD0481 where C2C3 possessed the SS configuration (Table 1) .
A closer look at the stereo-structure activity relationship (SSAR) reveals that the IFN-γ-dependent growth restriction of T. gondii is more closely dependent on absolute stereochemistry at position C3 of azetidine ring compared to C1 and C2. Compounds with (S) configuration at C3 (e.g. BRD7522, BRD4624, BRD0481, BRD6698) show greater IFN-γ-dependent growth restriction than the corresponding (RRR) isomers (e.g. BRD5882, BRD6541, BRD7523, BRD0367) ( Fig. 7, Table 1 ).
Among the compounds with (SSS) configuration, the compound with 'all-cis' configuration around the azetidine ring (BRD4624) shows highest IFN-γ-dependent growth restriction (Fig. 7, Table 1 ).
Conclusions
We developed a HTS to identify small molecules that exhibit growth inhibition of T. gondii that was enhanced by IFN-γ. A number of these inhibitors increased LC3 recruitment to the parasite containing vacuole, consistent with previous reports that a non-canonical autophagy pathway restricts intracellular growth of T. gondii (14) . However, at least half of the IFN-γ-dependent inhibitors identified here did not work through enhanced LC3 recruitment, as shown by the low correlation between LC3 recruitment and IFN-γ enhancement. Thus in addition to enhancing LC3 recruitment, it appears that IFN-γ can enhance the inhibitory effect of small molecules through other pathways yet to be elucidated. Although the effect of IFN-γ enhancement was modest ranging from 1-3 fold, this property was often consistently seen within a chemical series, suggesting that it is attributable to features of the compound structure.
Comparison of one series exemplified by BRD7522 revealed that specific stereoisomers were more strongly associated with inhibition and IFN-γ-dependence, suggesting a specific structural feature of the compounds are responsible for these effects. Hence, synthesis of additional analogs based on the hits discovered here might be exploited to enhance both potency and IFN-γ-dependence. The use of compounds that are synergistic with immune responses may allow more effective treatment at lower drug concentrations, thus minimizing adverse outcomes associated with antibiotic use.
Experimental Section
Parasite strains and culture
Toxoplasma gondii tachyzoites (ME49-FLUC, type II) (27) were serially passaged in human foreskin fibroblasts (HFF) cultured in complete DMEM medium (DMEM supplemented with 10% fetal bovine serum (FBS), glutamine (10 mM) and gentamycin (10 µg/mL)). For each assay described, infected monolayers were scraped, needle passed (23 ga), and parasites separated from host cell debris using a 3 micron pore polycarbonate filter. HeLa cells were cultured in MEM media that contained 10% FBS, 4 mM L-glutamine and 10 mM HEPES solution. For GFP-LC3 HeLa cell lines, the MEM media described above was supplemented with G418 (50 µg/mL) to maintain the expression plasmid. Cell culture and assays were conducted using a 37°C incubator with 5% CO 2 . Cell cultures were negative for mycoplasma, as determined using the e-Myco plus kit (Intron Biotechnology). 
Luciferase based growth assays: Titration of IFN-γ dependence
Scaling the assay to 384 well plate format
A high throughput screening (HTS) assay was miniaturized from a 96-well to a 384-well plate format to allow for more efficient screening. On day 1, HeLa cells (ATCC CCL-2) were plated in 384-well white plates at a density of 1,000 cells/well (20 µL total volume) in DMEM with 10% Fetal bovine serum (Hyclone) and allowed to settle. The following day, cells were activated with IFN-γ (1.25 U/mL, 10 µL volume ) and returned to the incubator for 24 h. On day 3, 100 nL of library compound was added to each well of the assay plates using a pin transfer method yielding a concentration of 20 µM compound in each assay well. Freshly egressed ME49-FLUC parasites were diluted to 4,000 parasites/well (MOI =1, 20 µL volume) and added to each well, resulting in a 10 µM final compound concentration (50 µL, final well volume). For compound transfer/infection runs greater than 2 h, fresh parasites were harvested every 2 h and resupplied to the automation platform to ensure consistent infection. On day 6, 30 µL of Steady-Glo reagent (Promega) was added to each well and after a brief incubation the Luminescence was detected on an Envision multi-mode plate reader (Perkin Elmer). To test for possible toxicity, HeLa cells were incubated with 20 µM compound (50 µL, final well volume) for 72 h and viability was assessed by measuring steady state ATP levels using the CellTiter-Glo reagent (Promega). Compounds that showed a reduction in ATP levels by 50% were eliminated.
Compound libraries
Compounds were chosen from a diverse unbiased collection of compounds drawn from the commercial libraries, including WuXi, Asinex, ChemBridge, ChemDiv, Enamine, MayBridge, Sigma, the Broad Institute Diversity Oriented Synthesis (DOS) library and a FDA repurposing collection of FDA approved and clinical candidates assembled at the Broad Institute (28) . All compounds were assembled and sourced at the Broad Institute. At the time of purchase, these commercial collections were prescreened using a computation chemistry algorithm to identify and exclude all PAIN compounds. A computational chemistry search was used to identify a subset of plates within the larger composite chemical library to maximize the chemical diversity of compounds screened in this HTS effort. At the time of pulling the compounds out of storage for retesting at dose, the compounds were put through a quality control step to ensure all compounds were of the correct mass and greater than 85% pure. Multi-Mode Imager using these parameters: dispense 100 µL LAR, shake 1 sec, read well at 10 sec post injection.
Luciferase based growth assays: validation of hits
Multi-point dose response (EC 50 determination).
White, clear bottom 96-well assay plates were set up as described above with the following modifications. Only the inner 60 wells were used for the assay in order to reduce variability that results from evaporation during incubation. Dilution of compound stock is as described above, with all wells containing a final concentration of 0.1% DMSO. Compounds were compared using 2-fold-serial dilution from 20 µM to 0.04 µM in the absence vs. presence of IFN-γ (5 or 10 U/ml). DMSO (vehicle control) and pyrimethamine (2.5 µM, positive control) were included in the outside wells of all plates as controls. Liquid handling (serial dilutions, compound dilutions, cell feeding, plate-to-plate transfers, etc) utilized a Dual Pod Biomek FX. Luciferase assays were performed using the integrated and automated platform (Beckman Coulter). The SAMI EX software was used to design and execute the screening assay and enabled efficient and uniform assay execution across all the assay plates. All steps and assays were completed at the High Throughput Screening Center at Washington University School of Medicine as described above.
Image based GFP-LC3 recruitment assay
GFP-LC3 HeLa cells were plated in 96-well, µClear black microplates (Greiner Bio-One, #655090) at a density of 1.8x10 4 cells/well and incubated overnight at 37°C. Cells were activated for 24 h with low dose IFN-γ (5 U/mL, 100 µL/well) or left naïve (100 µL/well), followed by a 4 h pretreatment with indicated compounds (5 µM, final concentration, see above for stock compound dilution and final DMSO % in each well) prior to the addition of ME49-FLUC parasites (5x10 4 parasites/well in 50 µL; 200 µL/well final volume). After 2 h, wells were rinsed 3 times in culture media to remove extracellular parasites and returned to normal culture media. Cells were fixed 6 h post-infection with 4% formaldehyde, permeabilized with 0.05% saponin and stained for indirect immunofluorescence. GFP-LC3 was localized using a mouse monoclonal antibody 3E6 (Life Technologies) and detected by Alexa Fluor 488 (Invitrogen). Parasite containing vacuoles were localized using rabbit polyclonal serum against type I parasites (RH) and detected using Alexa Fluor 594 (Invitrogen). Images were collected on a Cytation 3 imager and positive recruitment events were defined as overlap of GFP-LC3 signal (green) with T. gondii (red) signal that met minimum thresholds for a positive interaction (green: ≥ 55,000 units; red; size requirement range from 5 to 11 microns and signal >5,000 units).
Statistics
All results are presented as the average of two or more biological replicates. Linear regression analysis and dose-response inhibition (Log(inhibitor) vs. normalized response -variable slope) or (Log(inhibitor) vs normalized response) were performed in Prism 7 (GraphPad Software, Inc.).
Ancillary Information
Supporting Information: The primary screen evaluated 73,000 molecules for their capacity to restrict T. gondii tachyzoite replication in vitro (10 µM) using a luciferase-based growth assay. In parallel, the library was screened for cytotoxicity against HeLa cells (20 µM) to remove molecules that were toxic. Following the primary screen, 2,143 molecules were evaluated in an eight-point dose response assay in the presence of IFNγ (1.25 U/mL) that identified 880 compounds with EC 50 ≤ 10 µΜ. These 880 active compounds were retested in an eight-point dose response in the absence of IFN-γ. A total of 72 compounds that displayed IFN-γ-dependent growth inhibition were selected for further validation. After retesting, 15 compounds were selected for further study based on IFN-γ-dependent T. gondii growth restriction and enhanced recruitment of GFP-LC3 to the parasite containing vacuole. These core scaffolds were used to identify 61 analogs based on structure-activity relationship (SAR). Finally, 6 priority scaffolds were selected for further interrogation of IFN-γ-dependent potency against T. gondii. Table 1 . 
